Professional Documents
Culture Documents
This guidance represents the Food and Drug Administration's (FDA's) current thinking on this
topic. It does not create or confer any rights for or on any person and does not operate to bind
FDA or the public. You can use an alternative approach if the approach satisfies the
requirements of the applicable statutes and regulations.
I. Introduction
II. Discussion
III. Subpart A – General Provisions
IV. Written Procedures Required by the DS CGMP Rule
1 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
XI. Subpart G – Production and Process Control: Requirements For Components, Packaging,
And Labels And For Product That Is Received For Packaging Or Labeling As A Dietary
Supplement
XII. Subpart H – Production and Process Control: Requirements for a Master Manufacturing
Record
XIII. Subpart I – Production and Process Control: Requirements for a Batch Production Record
XIV. Subpart J – Production and Process Control: Requirements for Laboratory Operations
XV. Subpart K – Production and Process Control: Requirements for Manufacturing
Operations
XVI. Subpart L – Production and Process Control: Requirements for Packaging and Labeling
Operations
XVII. Subpart M – Holding and Distributing
XVIII. Subpart N – Returned Dietary Supplements
On June 25, 2007, FDA published in the Federal Register a final rule that established a
regulation (21 CFR part 111) entitled Current Good Manufacturing Practice (CGMP) In
Manufacturing, Packaging, Labeling, Or Holding Operations For Dietary Supplements (72 FR
34752). The Dietary Supplement (DS) CGMP rule in 21 CFR part 111 (“the DS CGMP rule”)
requires persons who manufacture, package, label, or hold a dietary supplement to establish
and follow current good manufacturing practice to ensure the quality of the dietary supplement
and to ensure that the dietary supplement is packaged and labeled as specified in the master
manufacturing record.
In the same issue of the Federal Register (72 FR 34959), FDA also issued an interim final rule
(the identity testing interim final rule) setting forth a procedure for requesting an exemption
from a requirement of the DS CGMP rule for the manufacturer to conduct at least one
appropriate test or examination to verify the identity of any dietary ingredient that is a
component of a dietary supplement. The provisions of the identity testing interim final rule have
the full force of law, but FDA provided a 90-day comment period on those provisions through
September 24, 2007. On September 17, 2007, FDA published a notice in the Federal Register to
extend the comment period to October 24, 2007.
The DS CGMP rule and the identity testing interim final rule were effective as of August 24,
2 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
FDA has prepared this Small Entity Compliance Guide in accordance with section 212 of the
Small Business Regulatory Enforcement Fairness Act (Public Law 104-121). This guidance
document restates in plain language the legal requirements set forth in the DS CGMP rule (21
CFR part 111). The DS CGMP rule is binding and has the full force and effect of law.
FDA's guidance documents, including this guidance, do not establish legally enforceable
responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should
be viewed only as recommendations, unless specific regulatory or statutory requirements are
cited. The use of the word should in Agency guidances means that something is suggested or
recommended, but not required.
3 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
You are subject to the DS CGMP rule if you manufacture, package, label, or hold a
dietary supplement.
4 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
You may be subject to the DS CGMP rule for products sold only within your state.
FDA may consider its jurisdiction over such products under the Public Health
Service Act, the Federal Food, Drug, and Cosmetic Act, or both, depending on the
circumstances of the situation.
(72 FR 34752 at 34785)
4. Am I subject to the holding requirements established in the DS CGMP
rule if I am a retailer who is holding dietary supplements at a retail
establishment for the sole purpose of direct retail sale to individual
consumers?
5 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Does not require you to comply with the requirement of 21 CFR 111.260(e) to
include the identity and weight or measure of each component used, because
you would be starting from packages that already had been filled rather than
from individual components.
As another example, if you are a distributor who purchases a packaged and labeled
dietary supplement and then holds the product in a warehouse for distribution to
another physical location, the DS CGMP rule:
Requires you to comply with requirements for holding and distributing; and
Requires you to comply with other applicable requirements, such as
requirements for personnel, the physical plant and grounds.
(21 CFR 111.1(a) and (a)(1); 72 FR 34752 at 34790 and 34886)
2. Am I subject to the DS CGMP rule if I manufacture a dietary ingredient
(or a “pre-mix” of dietary ingredients) used by another manufacturer to
make a dietary supplement?
Whether you are subject to the DS CGMP rule depends on the totality of your
business operation (72 FR 34752 at 34791). For example:
You are not subject to the DS CGMP rule if your only customers are other
manufacturers who further process the dietary ingredient to make a dietary
supplement (72 FR 34752 at 34791). However, we encourage firms who only
supply dietary ingredients to other firms for further processing as part of the
manufacture of a dietary supplement to adhere to the applicable provisions
established in the DS CGMP rule that apply to their operations (72 FR 34752 at
34805).
You would be subject to the DS CGMP ruleif you sell a dietary ingredient to a
firm who simply packages the dietary ingredient for sale as a dietary
supplement, or labels your packaged dietary ingredient for sale as a dietary
supplement, because in this circumstance you are manufacturing a dietary
supplement that another firm is simply packaging or labeling without further
processing into a dietary supplement (72 FR 34752 at 34791). In other words,
you would have acted as a manufacturer whose finished product is simply
repackaged or relabeled.
You would be subject to the DS CGMP rule if you supply a dietary ingredient
directly to consumers (72 FR 34752 at 34791); you would be considered a
dietary supplement manufacturer in such a situation.
3. Am I subject to the DS CGMP rule if I manufacture a dietary supplement
that is packaged or labeled by another firm – e.g., if I sell my dietary
supplement to another firm for packaging and labeling and do not sell
6 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
7 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
8 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
2. What are some examples of how the requirements of the DS CGMP rule
apply under contractual relationships?
Below, we provide three examples of how the requirements of the DS CGMP rule
apply under contractual relationships. Importantly, it is not practical to list all
possible contractual relationships that persons may enter into in the manufacture of
a dietary supplement, or to list all businesses or practices that may be subject to the
requirements of the DS CGMP rule.
Example 1. A manufacturer who contracts with a person to do packaging and
labeling, but who later distributes the packaged and labeled product, is
ultimately responsible for the dietary supplement it releases for distribution.
The manufacturer would be responsible for the CGMP requirements for the
operations it performs, including those related to the release of the product for
distribution. For example, the manufacturer would determine whether the
packaged and labeled dietary supplement it receives from the packager/labeler
conforms to applicable specifications (21 CFR 111.127(d)), and is responsible
for approving the release of the packaged and labeled dietary supplement for
9 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Batch;
Batch number, lot number, or control number;
Component;
Contact surface;
Ingredient;
In-process material;
Lot;
Microorganisms;
Pest;
Physical plant;
Product complaint;
10 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Quality;
Quality control;
You.
The text of these definitions is available in 21 CFR 111.3.
2. What definitions from the DS CGMP rule did we copy to this document?
We copied the definitions of the terms “quality” and “product complaint” (other than
the examples in such definition) to this document.
3. How does the DS CGMP rule define “quality”?
The DS CGMP rule defines “quality” to mean "that the dietary supplement
consistently meets the established specifications for identity, purity, strength, and
composition and limits on contaminants, and has been manufactured, packaged,
labeled, and held under conditions to prevent adulteration under sections 402(a)(1),
(a)(2), (a)(3), and (a)(4) of the act" [referring to the Federal Food, Drug, and
Cosmetic Act] (see 21 CFR 111.3).
4. How does the DS CGMP rule define “product complaint”?
The DS CGMP rule defines “product complaint” to mean "any communication that
contains any allegation, written, electronic, or oral, expressing concern, for any
reason, with the quality of a dietary supplement, that could be related to current
good manufacturing practice (see 21 CFR 111.3).
5. What does this document mean when it uses the terms “received
product” or “product received for packaging or labeling as a dietary
supplement”?
For the purposes of this document, we use the terms “received product” and
“product received for packaging or labeling as a dietary supplement” to mean
11 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
product you receive for packaging or labeling as a dietary supplement (and for
distribution rather than for return to the supplier).
6. What does this document mean when it uses the term “food CGMP”?
For the purposes of this document, we use the term “food CGMP” to mean the
CGMP requirements, in 21 CFR part 110, established for all food.
7. What does this document mean when it uses the term “required
specifications”?
For the purposes of this document, we use the term “required specifications” to
mean specifications that you are required to establish in accordance with 21 CFR
111.70.
8. What does this document mean when it uses the term “Certificate of
Analysis”?
For the purposes of this document, we use the term “certificate of analysis” to mean
a document, provided by the supplier of a component prior to or upon receipt of the
component, that documents certain characteristics and attributes of the component.
(72 FR 34752 at 34834)
9. What does this document mean when it uses the term “scientifically
valid method”?
For the purposes of this document, we use the term “scientifically valid method” to
mean a scientific method that is accurate, precise, and specific for its intended
purpose. In other words, we use the term “scientifically valid method” to mean a
scientific method that consistently does what it is intended to do.
Yes. You must comply with other applicable statutory provisions and regulations
under the Federal Food, Drug, and Cosmetic Act related to dietary supplements.
Duplicated those requirements in the food CGMP rule (i.e., 21 CFR part 110)
that we found to be common to most dietary supplements;
Did not duplicate those requirements in the food CGMP rule that were not
12 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
To the extent that the DS CGMP rule conflicts with the food CGMP rule, you would
comply with the DS CGMP rule.
13 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
1. What records does the DS CGMP rule require me to make and keep?
The DS CGMP rule requires you to make and keep the records shown in Table 4.
14 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
15 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
16 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
17 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Not eating food, chewing gum, drinking beverages, or using tobacco products in
areas where components, dietary supplements, or any contact surfaces are exposed,
or where contact surfaces are washed; and
Taking any other precautions necessary to protect against the contamination of
components, dietary supplements, or contact surfaces with microorganisms, filth, or
any other extraneous materials.
5. What does the DS CGMP rule require regarding personnel?
18 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
You have qualified employees who manufacture, package, label, or hold dietary
supplements (21 CFR 111.12(a));
You identify who is responsible for your quality control operations. Each person who
is identified to perform quality control operations must be qualified to do so and
such responsibilities must be distinct and separate from other responsibilities (21
CFR 111.12(b)); and
Each person engaged in manufacturing, packaging, labeling, or holding, or in
performing any quality control operations, to have the education, training, or
experience to perform the person's assigned functions (21 CFR 111.12(c)).
6. What does the DS CGMP rule require regarding supervisors?
The DS CGMP rule requires that:
1. What does the DS CGMP rule require regarding the physical plant and
grounds?
The DS CGMP rule:
Requires you to keep the grounds of your physical plant in a condition that protects
against the contamination of components, dietary supplements, or contact surfaces,
and establishes several specific measures for you to take to do this (21 CFR
111.15(a));
Requires you to maintain your physical plant in a clean and sanitary condition, and
in repair sufficient to prevent components, dietary supplements, or contact surfaces
from becoming contaminated (21 CFR 111.15(b)); and
19 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Examples of water that may become a component of a dietary supplement include water
that contacts components, dietary supplements, or any contact surface.
20 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
If you use a municipal water supply, you should take steps to ensure that you are at all
times aware of problems, such as an acute problem with microbial contamination or a
long-term problem associated with lead pipes present in some parts of the city water
supply, that may not be reflected in the municipal water report.
(72 FR 34752 at 34821)
7. What does the CGMP rule require regarding water from a private source,
such as a well, used in a manner such that the water may become a
component of the dietary supplement?
The DS CGMP rule requires that water from a private source, used in a manner such that
the water may become a component of the dietary supplement, comply with any State and
local requirements and not contaminate the dietary supplement. Satisfying this
requirement may involve performing appropriate water treatment procedures, including
filtration, sedimentation, and chlorination).
(21 CFR 111.15(e)(2); 72 FR 34752 at 34817)
1. What kinds of equipment and utensils are covered by the DS CGMP rule?
Equipment and utensils used in manufacturing, packaging, labeling or holding operations
that are covered by the DS CGMP rule include:
21 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
dietary supplement?
For any automated, mechanical, or electronic equipment that you use to manufacture,
package, label, or hold a dietary supplement, the DS CGMP rule requires you to:
Establish and use appropriate controls to ensure that the equipment functions in
accordance with its i ntended use. These controls must be approved by quality
control personnel (21 CFR 111.30(e)).
22 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
control operations?
Subpart E of the DS CGMP rule requires you to implement quality control
operations in your manufacturing, packaging, labeling, and holding operations for
producing the dietary supplement to ensure the quality of the dietary supplement
and that the dietary supplement is packaged and labeled as specified in the master
manufacturing record.
(21 CFR 111.65)
B. Requirements to Establish Specifications
1. What specifications does the DS CGMP rule require me to establish?
The DS CGMP rule requires you to establish:
A specification for any point, step, or stage in the manufacturing process where
control is necessary to ensure the quality of the dietary supplement and that
the dietary supplement is packaged and labeled as specified in the master
manufacturing record (21 CFR 111.70(a));
Specifications for dietary supplement labels and packaging (21 CFR 111.70(d));
Product specifications for the finished batch of the dietary supplement (21 CFR
111.70(e));
Specifications for product you receive from a supplier for packaging or labeling
as a dietary supplement (21 CFR 111.70(f)); and
Specifications for the packaging and labeling of the finished packaged and
labeled dietary supplements (21 CFR 111.70g)).
2. Does the DS CGMP rule require me to establish specifications for
parameters such as dissolution, disintegration, and bioavailability?
No.
23 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Specifications for product you receive from a supplier for packaging or labeling
as a dietary supplement (21 CFR 111.75(e));
Specifications for dietary supplement labels and packaging (21 CFR 111.75(f));
and
Specifications for the packaging and labeling of the finished packaged and
labeled dietary supplements (21 CFR 111.75(g)).
2. Should I have data to support any specifications I establish for
parameters such as dissolution, disintegration, and bioavailability?
Yes. Although the DS CGMP rule does not require you to establish specifications for
parameters such as dissolution, disintegration, and bioavailability, if you establish
such specifications you should have data to support that such specifications are met.
Yes. Although the DS CGMP rule does not require you to establish an “expiration
date” (or a “shelf date” or “best if used by” date), you should have data to support
any such date that you place on a product label.
(72 FR 34752 at 34855)
4. What does the DS CGMP rule require regarding the tests and
examinations I use to determine whether specifications are met?
You ensure that the tests and examinations you use to determine whether the
specifications are met are appropriate, scientifically valid methods (21 CFR
111.75(h)(1)); and
The tests and examinations you use include at least one of the following (21
CFR 111.75(h)(2)):
24 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
You select one or more established specifications for identity, purity, strength,
composition, and the limits on those types of contamination that may
adulterate or that may lead to adulteration of the dietary supplement that, if
determined to be in compliance with specifications by testing or examination
of the finished batch of the dietary supplement, would verify that the
production and process control system is producing a dietary supplement that
meets all product specifications (with the exception of those product
specifications that are exempted from this requirement) (21 CFR 111.75(c)(1)
and 21 CFR 111.75(d));
You conduct appropriate tests or examinations to determine compliance with
these specifications (21 CFR 111.75(c)(2));
You provide adequate documentation of your basis for determining that
compliance with the selected specification(s), through the use of appropriate
tests or examinations, will ensure that your finished batch of the dietary
supplement meets all product specifications established under 21 CFR
111.70(e) (21 CFR111.75(c)(3)); and
Your quality control personnel review and approve this documentation (21
CFR 111.75(c)(4)).
Yes (21 CFR 111.75(d)). We realize that there may well be some specifications that
you may not be able to test for at the finished batch stage. For example, you may
determine that you could not verify, by testing for compliance with the specifications
for identity and composition, that the purity specification is met, and there may be
25 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
no scientifically valid method for testing or examining the finished batch to evaluate
the purity in the finished batch of dietary supplement. In such a case, the DS CGMP
rule provides that you can document why, for example, any component and in-
process testing, examination, or monitoring, and any other information, will ensure
that this product specification is met without verification through periodic testing of
the finished batch, provided your quality control personnel review and approve that
documentation (21 CFR 111.75(d)). For example, you could exempt the specification
for purity from the requirement in 21 CFR 111.75(c)(1) through, for example,
documentation that meeting component and specifications for strength is sufficient,
or through documentation that in-process monitoring is sufficient, provided your
quality control personnel review and approve such documentation (21 CFR
111.75(d)).
The consequences of not meeting a specification that the DS CGMP rule requires you
to establish under 21 CFR 111.70 depend on which specification is not met (21 CFR
111.77). Table 5 shows these consequences.
26 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
27 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
28 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
The DS CGMP rule requires you to confirm the identity of components, and
determine whether other specifications for components (including dietary
ingredients), are met, either by conducting appropriate tests or examinations or by
relying on a certificate of analysis from the supplier of the component.
(21 CFR 111.75(a)(2))
4. What does the CGMP rule require me to do if I rely on a Certificate of
Analysis from a supplier to confirm the identity of a component other
than a dietary ingredient, or to determine whether any other component
specifications are met?
The DS CGMP rule requires that:
You first qualify the supplier by establishing the reliability of the supplier's
certificate of analysis through confirmation of the results of the supplier's tests
or examinations (21 CFR 111.75(a)(2)(ii)(A)).
29 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Your quality control personnel review and approve the documentation setting
forth the basis for qualification (and re-qualification) of any supplier (21 CFR
111.75(a)(2)(ii)(E)).
E. Requirements for Representative and Reserve Samples
1. What representative samples does the DS CGMP rule require me to
collect?
The DS CGMP rule requires you to collect representative samples of the following
materials:
Each unique lot of components, packaging, and labels that you use (21 CFR
111.80(a));
Each unique shipment, and each unique lot within each unique shipment, of
product that you receive for packaging or labeling as a dietary supplement (and
for distribution rather than for return to the supplier (21 CFR 111.80(d)); and
Each lot of packaged and labeled dietary supplements (21 CFR 111.80(e)).
2. Why does the DS CGMP rule require me to collect and to hold
representative samples?
30 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
The DS CGMP rule requires you to collect and hold reserve samples of each lot of
packaged and labeled dietary supplements that you distribute. This would include
dietary supplements that you package and label in bulk.
(21 CFR 111.83(a))
4. Why does the DS CGMP rule require me to collect and to hold reserve
samples of packaged and labeled dietary supplements?
The DS CGMP rule requires you to collect and hold reserve samples of packaged and
labeled dietary supplements for use in appropriate investigations, such as consumer
complaint investigations.
(21 CFR 111.83(b)(3) and 21 CFR 111.465(b))
5. How many reserve samples does the DS CGMP rule require me to collect
and hold?
The DS CGMP rule requires that the amount of reserve samples you collect and hold
consist of at least twice the quantity necessary for all tests or examinations to
determine whether or not the dietary supplement meets product specifications.
(21 CFR 111.83(b)(4))
The DS CGMP rule requires you to identify reserve samples with the batch, lot, or
control number.
(21 CFR 111.83(b)(2))
The DS CGMP rule requires you to use the following container-closure systems to
hold reserve samples of dietary supplements:
If you are distributing a dietary supplement for packaging and labeling, the DS
CGMP rule requires you to keep the reserve samples in a container-closure
system that provides essentially the same characteristics to protect against
contamination or deterioration as the one in which you distributed the dietary
supplement for packaging and labeling elsewhere. For example, if you
distribute product in bulk using a polyethylene bottle that can hold 50
31 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
kilograms of the product, and there is an air space above the product, you
would hold the reserve samples in a polyethylene bottle with an air space.
However, you would use a bottle sized to fit the smaller amount you are
holding in reserve.
(21 CFR 111.83(b)(1); 72 FR 34752 at 34904)
8. How long does the DS CGMP rule require me to hold reserve samples of
packaged and labeled dietary supplements?
The DS CGMP rule requires you to hold reserve samples of packaged and labeled
dietary supplements for:
One year past the shelf life date (if shelf life dating is used); or
Two years from the date of distribution of the last batch of dietary supplements
associated with the reserve sample.
(21 CFR 111.83(b)(3); 72 FR 34752 at 34905)
1. What does the DS CGMP rule require quality control personnel to do?
The DS CGMP rule requires quality control personnel to ensure that your manufacturing,
packaging, labeling, and holding operations ensure the quality of the dietary supplement
and that the dietary supplement is packaged and labeled as specified in the master
manufacturing record.
The DS CGMP rule requires quality control personnel to perform operations that include:
Approving or rejecting all processes, specifications, written procedures, controls,
tests, and examinations, and deviations from or modifications to them, that may
affect the identity, purity, strength, or composition of a dietary supplement (21 CFR
111.105(a));
Reviewing and approving the documentation setting forth the basis for qualification
of any supplier (21 CFR 111.105(b));
Reviewing and approving the documentation setting forth the basis for why meeting
in-process specifications, in combination with meeting component specifications,
will help ensure that the identity, purity, strength, and composition of the dietary
supplement are met (21 CFR 111.105(c));
32 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Reviewing and approving the documentation setting forth the basis for why the
results of appropriate tests or examinations for each product specification selected
under 21 CFR 111.75(c)(1) will ensure that the finished batch of the dietary
supplement meets product specifications (21 CFR 111.105(d));
Reviewing and approving the basis and the documentation for why any product
specification is exempted from the verification requirements in 21 CFR 111.75(c)(1),
and for why any component and in-process testing, examination, or monitoring, or
other methods will ensure that such exempted product specification is met without
verification through periodic testing of the finished batch (21 CFR 111.105(e));
Ensuring that all representative samples are collected (21 CFR 111.105(f));
Ensuring that all reserve samples are collected and held (21 CFR 111.105(g));
Determining whether all specifications established under 21 CFR 111.70(a) are met
(21 CFR 111.105(h));
Laboratory operations (21 CFR 111.110);
Operations regarding material review and disposition decisions (21 CFR 111.113);
Operations regarding equipment, instruments, and controls (21 CFR 111.117);
Operations regarding components, packaging, and labels before use in the
manufacture of a dietary supplement (21 CFR 111.120);
Operations regarding the master manufacturing record, the batch production record,
and manufacturing operations (21 CFR 111.123);
Packaging and labeling operations (21 CFR 111.127);
Operations regarding returned dietary supplements (21 CFR 111.130); and
The DS CGMP rule identifies five circumstances when quality control personnel must
conduct a material review and make a disposition decision (21 CFR 111.113(a)):
A specification established in accordance with 21 CFR 111.70 is not met (21 CFR
111.113(a)(1));
A batch deviates from the master manufacturing record, including when any step
33 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
established in the master manufacturing record is not completed and including any
deviation from specifications (21 CFR 111.113(a)(2));
There is any unanticipated occurrence during the manufacturing operations that
adulterates or may lead to adulteration of the component, dietary supplement, or
packaging, or could lead to the use of a label not specified in the master
manufacturing record (21 CFR 111.113(a)(3));
Calibration of an instrument or control suggests a problem that may have resulted in
a failure to ensure the quality of a batch or batches of a dietary supplement (21 CFR
111.113(a)(4)); or
A dietary supplement is returned (21 CFR 111.113(a)(5)).
5. When does the DS CGMP rule require quality control personnel to reject a
component, dietary supplement, packaging or label?
The DS CGMP rule requires quality control personnel to reject a component, dietary
supplement, packaging, or label when:
When a specification that you are required to establish is not met (unless quality
control personnel approve a treatment, an in-process adjustment, or reprocessing,
as permitted in 21 CFR 111.77) (21 CFR 111.113(b)(2)).
The DS CGMP rule requires the person who conducts a material review and makes the
disposition decision to document the material review and disposition decision at the time
of performance.
(21 CFR 111.113(c))
34 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Quality control personnel release the components from quarantine (21 CFR
111.155(c)(3)).
3. Does the DS CGMP rule require me to assign a unique identifier to
components?
Yes. The DS CGMP rule requires you to identify each unique lot within each unique
shipment of components you receive (and any lot of components you produce) in a
manner that allows you to trace the lot to the supplier, the date received, the name of
the component, the status of the component (e.g., quarantined, approved, or
rejected), and to the dietary supplement that you manufactured and distributed.
(21 CFR 111.155(d)(1))
4. When does the DS CGMP rule require me to use the unique identifier
that I assign to components?
The DS CGMP rule requires you to use this unique identifier whenever you record
the disposition of each unique lot within each unique shipment of components you
receive and any lot of components you produce.
(21 CFR 111.155(d)(2))
35 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
The DS CGMP rule requires you to visually examine the supplier's invoice,
guarantee, or certification, and each immediate container or grouping of immediate
containers, in a shipment.
(21 CFR 111.160(a) and (b))
2. How long does the DS CGMP rule require me to quarantine packaging
and labels?
The DS CGMP rule requires you to quarantine packaging and labels until:
Quality control personnel review and approve the results of any tests or
examinations conducted on the packaging and labels (21 CFR 111.160(c)(2));
Quality control personnel approve the packaging and labels for use in the
manufacture of a dietary supplement (21 CFR 111.160(c)(3)); and
Quality control personnel release the packaging and labels from quarantine (21
CFR 111.160(c)(3)).
3. Does the DS CGMP rule require me to assign a unique identifier to
packaging and labels?
36 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Yes. The DS CGMP rule requires you to identify each unique lot within each unique
shipment of packaging and labels in a manner that allows you to trace the lot to the
supplier, the date received, the name of the packaging and label, the status of the
packaging and label (e.g., quarantined, approved, or rejected), and to the dietary
supplement that you distributed.
The DS CGMP rule requires you to hold packaging and labels under conditions that
will protect against contamination and deterioration, and avoid mix-ups.
(21 CFR 111.160(e))
The DS CGMP rule requires you to visually examine the supplier's invoice,
guarantee, or certification, and each immediate container or grouping of immediate
containers, in a shipment.
(21 CFR 111.165(a) and (b))
2. How long does the DS CGMP rule require me to quarantine received
product?
The DS CGMP rule requires you to quarantine received product until:
37 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
38 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
manufacture, and for each batch size, to ensure uniformity in the finished batch from
batch to batch (21 CFR 111.205(a)). The master manufacturing record must establish
controls and procedures to ensure that each batch of dietary supplement you manufacture
meets those specifications (21 CFR 111.205(b)(2)).
2. What specifications does the DS CGMP rule require the master
manufacturing record to identify?
The DS CGMP rule requires the master manufacturing record to identify specifications for
the points, steps, or stages in the manufacturing process where control is necessary to
ensure the quality of the dietary supplement and that the dietary supplement is packaged
and labeled as specified in the master manufacturing record.
(21 CFR 111.205(b))
3. What does the DS CGMP rule require the master manufacturing record to
include?
The DS CGMP rule requires the master manufacturing record to include:
The name of the dietary supplement to be manufactured and the strength,
concentration, weight, or measure of each dietary ingredient for each batch size (21
CFR 111.210(a));
A complete list of components to be used (21 CFR 111.210(b));
An accurate statement of the weight or measure of each component to be used (21
CFR 111.210(c));
The identity and weight or measure of each dietary ingredient that will be declared
on the Supplement Facts label and the identity of each ingredient that will be
declared on the ingredients list of the dietary supplement (21 CFR 111.210(d));
A statement of any intentional overage amount of a dietary ingredient (21 CFR
111.210(e)) (the amount of overage should be limited to the amount needed to meet
the weight or measure of each dietary ingredient that will be declared on the
Supplement Facts label of the dietary supplement) (72 FR 34752 at 34884);
A statement of theoretical yield of a manufactured dietary supplement expected at
each point, step, or stage of the manufacturing process where control is needed to
ensure the quality of the dietary supplement, and the expected yield when you finish
manufacturing the dietary supplement, including the maximum and minimum
percentages of theoretical yield beyond which a deviation investigation of a batch is
necessary and material review is conducted and disposition decision is made (21
CFR 111.210(f));
A description of packaging and a representative label, or a cross-reference to the
physical location of the actual or representative label (21 CFR 111.210(g)); and
39 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Specific actions necessary to perform and verify points, steps, or stages in the
manufacturing process where control is necessary to ensure the quality of the
dietary supplement and that the dietary supplement is packaged and labeled as
specified in the master manufacturing record (21 CFR 111.210(h)(3));
Such specific actions must include verifying the weight or measure of any
component and verifying the addition of any component (21 CFR
111.210(h)(3)(i)); and
For manual operations, such specific actions must include one person
weighing or measuring a component and another person verifying the
weight or measure, and one person adding the component and another
person verifying the addition (21 CFR 111.210(h)(3)(ii));
40 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
The DS CGMP rule requires the batch production record to include complete information
relating to the production and control of each batch (21 CFR 111.255(b)). Specifically, the
DS CGMP rule requires the batch production record to include:
The batch, lot, or control number of the finished batch of dietary supplement, each
lot of packaged and labeled dietary supplement from the finished batch of dietary
supplement, and each lot of dietary supplement, from the finished batch of dietary
supplement, that you distribute to another person for packaging or labeling (21 CFR
111.260(a));
The identity of equipment and processing lines used in producing the batch (21 CFR
111.260(b));
The date and time of the maintenance, cleaning, and sanitizing of the equipment and
processing lines used in producing the batch, or a cross-reference to records, such as
individual equipment logs, where this information is retained (21 CFR 111.260(c));
The unique identifier you assigned to each component (or, when applicable, to a
product that you receive from a supplier for packaging or labeling as a dietary
supplement), packaging, and label used (21 CFR 111.260(d));
The identity and weight or measure of each component used (21 CFR 111.260(e));
A statement of the actual yield and a statement of the percentage of theoretical yield
at appropriate phases of processing (21 CFR 111.260(f));
The actual results obtained during any monitoring operation (21 CFR 111.260(g));
The results of any testing or examination performed during the batch production, or
a cross-reference to such results (21 CFR 111.260(h));
Documentation that the finished dietary supplement meets specifications
established in accordance with 21 CFR 111.70(e) and (g) (21 CFR 111.260(i));
41 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
1. What does the DS CGMP rule require regarding facilities to perform testing
and examinations?
The DS CGMP rule requires you to use adequate laboratory facilities to perform testing
and examinations.
(21 CFR 111.310)
2. What laboratory control processes does the DS CGMP rule require me to
establish and follow?
The DS CGMP rule requires you to establish and follow laboratory control processes that
include:
Use of criteria for establishing appropriate specifications (21 CFR 111.315(a));
Use of sampling plans for obtaining representative samples (21 CFR 111.315(b));
Use of criteria for selecting appropriate examination and testing methods (21 CFR
111.315(c));
Use of criteria for selecting standard reference materials used in performing tests
and examinations (21 CFR 111.315(d)); and
Use of test methods and examinations in accordance with established criteria (21
CFR 111.315(e)).
3. Does the DS CGMP rule require quality control personnel to review and
approve the laboratory control processes I establish and follow?
Yes.
42 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Verify that the laboratory examination and testing methodologies are appropriate for
their intended use (21 CFR 111.320(a)); and
Identify and use an appropriate scientifically valid method for each established
specification for which testing or examination is required to determine whether the
specification is met (21 CFR 111.320(b)).
6. What is an example of a scientifically valid method?
An example of a scientifically valid method can be one that is based on scientific data or
results published in, for example, scientific journals, references, text books, or proprietary
research.
43 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
The DS CGMP rule requires you to take all necessary precautions during the manufacture
of a dietary supplement to prevent contamination of components or dietary supplements,
including the following specific precautions:
Performing manufacturing operations under conditions and controls that protect
against the potential for growth of microorganisms and the potential for
contamination (21 CFR 111.365(a));
44 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Washing or cleaning components that contain soil or other contaminants (21 CFR
111.365(b));
Using water that, at a minimum, complies with the applicable Federal, State, and
local requirements and does not contaminate the dietary supplement when the water
may become a component of the finished batch of dietary supplement (21 CFR
111.365(c));
Performing chemical, microbiological, or other testing, as necessary to prevent the
use of contaminated components (21 CFR 111.365(d));
Sterilizing, pasteurizing, freezing, refrigerating, controlling hydrogen-ion
concentration (pH), controlling humidity, controlling water activity (aw), or using
any other effective means to remove, destroy, or prevent the growth of
microorganisms and prevent decomposition (21 CFR 111.365(e));
Holding components and dietary supplements that can support the rapid growth of
microorganisms of public health significance in a manner that prevents the
components and dietary supplements from becoming adulterated (21 CFR
111.365(f));
Identifying all processing lines and major equipment used during manufacturing to
indicate their contents, including the name of the dietary supplement and the
specific batch or lot number and, when necessary, the phase of manufacturing (21
CFR 111.365(k)).
4. What does the DS CGMP rule require me to do with a rejected dietary
supplement?
The DS CGMP rule requires you to clearly identify, hold, and control under a quarantine
system for appropriate disposition any dietary supplement that is rejected and unsuitable
45 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
46 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
Identifying, by any effective means, filled dietary supplement containers that are set
aside and held in unlabeled condition for future label operations, to prevent mix-ups
(21 CFR 111.415(e));
Assigning a batch, lot, or control number to each lot of packaged and labeled dietary
supplement from a finished batch of dietary supplement and each lot of dietary
supplement, from a finished batch of dietary supplement, that you distribute to
another person for packaging or labeling (21 CFR 111.415(f));
Examining a representative sample of each batch of the packaged and labeled dietary
supplement to determine whether the dietary supplement meets specifications
established in accordance with 21 CFR 111.70(g) (21 CFR 111.415(g)); and
Suitably disposing of labels and packaging for dietary supplements that are obsolete
or incorrect to ensure that they are not used in any future packaging and label
operations (21 CFR 111.415(h)).
You may repackage or relabel a dietary supplement only after quality control personnel
have approved such repackaging or relabeling.
47 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
6. What does the DS CGMP rule require me to do with a packaged and labeled
dietary supplement that is rejected for distribution?
The DS CGMP rule requires you to clearly identify, hold, and control under a quarantine
system for appropriate disposition any packaged and labeled dietary supplement that is
rejected for distribution.
(21 CFR 111.425)
Hold packaging and labels under appropriate conditions so that the packaging and
labels are not adversely affected (21 CFR 111.455(b));
Hold components, dietary supplements, packaging, and labels under conditions that
do not lead to the mix-up, contamination, or deterioration of components, in-
process materials, dietary supplements, packaging, and labels (21 CFR 111.455(c));
Identify and hold in-process material under conditions that protect against mix-up,
contamination, and deterioration (21 CFR 111.460(a)); and
The DS CGMP rule requires you to use the following container-closure systems to hold
reserve samples of dietary supplements:
If you are distributing a packaged and labeled dietary supplement, the DS CGMP
rule requires you to keep the reserve samples in a container-closure system that is
the same as the container-closure system in which the dietary supplement is
distributed.
48 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
If you are distributing a dietary supplement for packaging and labeling, the DS
CGMP rule requires you to keep the reserve samples in a container-closure system
that provides essentially the same characteristics to protect against contamination or
deterioration as the one in which you distributed the dietary supplement for
packaging and labeling elsewhere. For example, if you distribute product in bulk
using a polyethylene bottle that can hold 50 kilograms of the product, and there is an
air space above the product, you would hold the reserve samples in a polyethylene
bottle with an air space. However, you would use a bottle sized to fit the smaller
amount you are holding in reserve.
(21 CFR 111.83(b)(1); 21 CFR 111.465(a)(2); 72 FR 34752 at 34904)
4. How does the DS CGMP rule require me to hold reserve samples of packaged
and labeled dietary supplements?
The DS CGMP rule requires you to hold reserve samples under conditions consistent with
product labels or, if no storage conditions are recommended on the label, under ordinary
storage conditions. For example, if the product label states “Keep this product
refrigerated,” you would store the reserve sample in a refrigerator.
(21 CFR 111.465(a)(1))
5. How long does the DS CGMP rule require me to hold reserve samples of
packaged and labeled dietary supplements?
The DS CGMP rule requires you to hold reserve samples of packaged and labeled dietary
supplements for:
One year past the shelf life date (if shelf life dating is used); or
Two years from the date of distribution of the last batch of dietary supplements
associated with the reserve sample.
(21 CFR 111.83(b)(3) and 111.465(b))
6. What does the DS CGMP rule require me to do when distributing dietary
supplements?
The DS CGMP rule requires you to distribute dietary supplements under conditions that
will protect the dietary supplements against contamination and deterioration.
(21 CFR 111.470)
49 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
You ensure that any returned dietary supplements that are reprocessed meet all
product specifications established for the finished batch to ensure the quality of the
dietary supplement(21 CFR 111.525(a)); and
Quality control personnel approve or reject the release for distribution of any
returned dietary supplement that is reprocessed (21 CFR 111.525(b)).
5. When does the DS CGMP rule require me to conduct an investigation of my
manufacturing processes and other batches following the return of a
product?
The DS CGMP rule requires you to conduct an investigation of your manufacturing
processes and each of those other batches to determine compliance with specifications if
the reason for a dietary supplement being returned implicates other batches.
(21 CFR 111.530)
50 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
A qualified person review all product complaints to determine whether the product
complaint involves a possible failure of a dietary supplement to meet any of its
specifications, or any other requirements of part 111, including those specifications
and other requirements that, if not met, may result in a risk of illness or injury (21
CFR 111.560(a)(1));
51 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
52 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
for how serious adverse event reports are to be submitted to FDA and recordkeeping
requirements relating to adverse event reports. We encourage firms who are unsure as to
whether an adverse event should be reported to FDA to contact us for assistance (72 FR
34752 at 34909). FDA has also published guidance for industry about mandatory dietary
supplement adverse event reporting and recordkeeping requirements, entitled "Questions
and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary
Supplements as Required by the Dietary Supplement and Nonprescription Drug
Consumer Protection Act," (Ref. 3).
1. What does the DS CGMP rule require regarding the records that I make and
keep?
The DS CGMP rule requires that:
You keep written records for one year past the shelf life date (if shelf life dating is
used), or for 2 years beyond the date of distribution of the last batch of dietary
supplements associated with those records (21 CFR 111.605(a));
All electronic records comply with 21 CFR part 11 (21 CFR 111.605(c)).
2. What does the DS CGMP rule require me to do to make records available to
FDA?
The DS CGMP rule requires you to:
Have all required records, or copies of such records, readily available during the
retention period for inspection and copying by FDA when requested (21 CFR
111.610(a)); and
Make suitable reader and photocopying equipment readily available to FDA if you
use reduction techniques, such as microfilming (21 CFR 111.610(b)).
We have placed the following references on display in the Division of Dockets Management,
Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. You may
see them at that location between 9 a.m. and 4 p.m., Monday through Friday. As of November 9,
2010, FDA had verified the Web site address for the references it makes available as hyperlinks
from the Internet copy of this guidance.
1. FDA. Guidance for Industry: Product Recalls, Including Removals and Corrections
53 of 54 04-Feb-20, 10:58 AM
Small Entity Compliance Guide: Current Good Manufacturing Practice ... https://www.fda.gov/regulatory-information/search-fda-guidance-docum...
(/safety/industry-guidance/guidance-industry-product-recalls-including-removals-and-
corrections).
2. FDA. Report a Problem. How to Report Problems With Products Regulated by FDA.
3. FDA. Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for
Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug
Consumer Protection Act (/food/guidance-documents-regulatory-information-
topic/guidance-industry-questions-and-answers-regarding-adverse-event-reporting-and-
recordkeeping-dietary).
54 of 54 04-Feb-20, 10:58 AM